Showing 175 news articles about New & experimental hepatitis C treatment

Filters Content type: News Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

New & experimental hepatitis C treatment

European and US regulators approve AbbVie's new combo for all hepatitis C genotypes

News
7 August 2017
New & experimental hepatitis C treatment

Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection

News
26 July 2017
New & experimental hepatitis C treatment

US regulator approves Gilead's Vosevi combo pill for hepatitis C retreatment

News
19 July 2017
New & experimental hepatitis C treatment

New pangenotypic hepatitis C drug combinations recommended for approval in the European Union

News
26 June 2017
New & experimental hepatitis C treatment

Triple combination cures most hepatitis C patients with prior DAA treatment failure

News
28 April 2017
New & experimental hepatitis C treatment

AbbVie combination cures 95% of genotype 3 hepatitis C

News
21 April 2017
New & experimental hepatitis C treatment

New AbbVie hepatitis C combination cures 99% of people with cirrhosis

News
21 April 2017
Hepatitis & HIV

Glecaprevir/pibrentasvir for hepatitis C can be safely administered with common antiretrovirals

News
10 March 2017
Hepatitis C treatment

Sofosbuvir/velpatasvir shows high cure rate in HIV/HCV co-infection study

News
21 July 2016
Hepatitis C treatment

WHO issues new hepatitis C guidelines, EASL guidelines update forthcoming in September

News
12 May 2016
Hepatitis C treatment

Portugal's roll-out of HCV therapy with DAAs achieves impressive results

News
27 April 2016
Hepatitis C treatment

DAAs achieve excellent outcomes in real-world settings

News
21 April 2016
New & experimental hepatitis C treatment

Sofosbuvir/velpatasvir + GS-9857 works well for treatment-experienced hepatitis C patients

News
15 April 2016
New & experimental hepatitis C treatment

Ravidasvir plus sofosbuvir demonstrates high cure rate for people with hepatitis C genotype 4

News
8 March 2016
New & experimental hepatitis C treatment

New Merck combination pill Zepatier approved for hepatitis C treatment in the United States

News
1 February 2016
Hepatitis C treatment

A quarter of people with HCV initially refused access to sofosbuvir/lepidasvir, says US study, but most successfully appeal

News
29 December 2015
New & experimental hepatitis C treatment

Grazoprevir/elbasvir cures more than 90% of people with HIV/HCV co-infection

News
11 December 2015
New & experimental hepatitis C treatment

Triple DAA regimen cures hepatitis C patients with rapid response in just 3 weeks

News
26 November 2015
New & experimental hepatitis C treatment

Daclatasvir plus sofosbuvir works well for people with genotype 3 hepatitis C and advanced liver disease in real-world clinical practice

News
20 November 2015
New & experimental hepatitis C treatment

Daclatasvir and sofosbuvir with ribavirin cures 90% of people with genotype 3 hepatitis C

News
20 November 2015
New & experimental hepatitis C treatment

New AbbVie hepatitis C combination cures 93 to 97% with genotype 3

News
18 November 2015
New & experimental hepatitis C treatment

Sofosbuvir/ledipasvir plus vedroprevir shows 96% response rate for hard-to-treat genotype 1 hepatitis C patients

News
18 November 2015
New & experimental hepatitis C treatment

Sofosbuvir/velpatasvir shows high cure rates for all HCV genotypes, works well for patients with liver decompensation

News
17 November 2015
New & experimental hepatitis C treatment

Sofosbuvir & ravidasvir delivers high sustained response rates for genotype 4 hepatitis C patients

News
17 November 2015